ABC Laboratories Announces Expanded Large Molecule Drug Development Services

Recent Investment in Biomolecule Drug Development Capabilities Complements ABC Laboratories' Long History of ELISA, RIA and EIA Experience, and Leverages ABC's Extensive Analytical Capabilities

COLUMBIA, Mo.--(BUSINESS WIRE)--Recognizing an increased industry need for outsourced biopharmaceutical drug development services, Analytical Bio-Chemistry Laboratories (ABC) has expanded its offering to include comprehensive support for large molecule development.

“Recent investments in people, processes and systems have resulted in 13% growth over 2008 and positioned us well to deliver on our customer’s needs in the years to come.”

"ABC Laboratories’ recent investment in expanded biomolecule development capabilities complements our company’s long history of ELISA, RIA and EIA experience and bioanalytical support. It also leverages ABC's extensive analytical capabilities to provide our clients with more comprehensive support for both large and small molecules," said John Bucksath, General Manager and Senior Vice President of ABC's Pharmaceutical Services division.

To lead the development of a dedicated biotech team and laboratory, ABC recruited industry veteran, John C. Anders, Ph.D., who brings more than 24 years of experience in drug development from both the sponsor and Contract Research Organization (CRO) side of the business. Over his distinguished career, Dr. Anders has held several leadership positions building and leading advanced CGMP large molecule analytical laboratories, and has expertise in time-tested and new technologies in protein chemistry, analytical methods and analysis of macromolecules by various methods. He played a major role in developing a pipeline of seven genomic expression tests for diagnosis and risk assessment of various types of cancer, including the successful completion of a pre-IND application to the FDA and development of a clinical protocol slated to begin soon.

Dr. Anders has assembled a team of biopharmaceutical experts, each with more than 18 years of experience in protein chemistry and chromatography. To ensure the team is well equipped to meet client demand, ABC has invested in a leading-edge biotech lab housed in ABC’s new, 90,000 square-foot pharmaceutical development facility in Columbia, Missouri.

“Despite a challenging economic environment, 2009 was a positive year for ABC Laboratories,” said Bucksath. "Recent investments in people, processes and systems have resulted in 13% growth over 2008 and positioned us well to deliver on our customer’s needs in the years to come.”

About ABC Laboratories

Analytical Bio-Chemistry (ABC) Laboratories, Inc. is a leading provider of contract development services to the pharmaceutical, animal health and chemical industries. The company supports all stages of drug development and chemical product registrations worldwide with expert analytical chemistry and value-added development services.

For additional information, visit http://www.abclabs.com.